LUPPI, MARIO
Distribuzione geografica
Continente | # |
---|---|
EU - Europa | 25 |
NA - Nord America | 15 |
AS - Asia | 9 |
OC - Oceania | 1 |
Totale | 50 |
Nazione | # |
---|---|
US - Stati Uniti d'America | 15 |
IT - Italia | 9 |
CN - Cina | 5 |
GB - Regno Unito | 4 |
FR - Francia | 3 |
ES - Italia | 2 |
JP - Giappone | 2 |
AD - Andorra | 1 |
BE - Belgio | 1 |
DE - Germania | 1 |
IE - Irlanda | 1 |
KR - Corea | 1 |
NL - Olanda | 1 |
NZ - Nuova Zelanda | 1 |
PL - Polonia | 1 |
RS - Serbia | 1 |
TH - Thailandia | 1 |
Totale | 50 |
Città | # |
---|---|
Brooklyn | 3 |
Wembley | 3 |
Monza | 2 |
Rome | 2 |
San Fernando | 2 |
Shanghai | 2 |
Amsterdam | 1 |
Ashburn | 1 |
Atlanta | 1 |
Bang Bai Mai | 1 |
Belgrade | 1 |
Boardman | 1 |
Brussels | 1 |
Cedar Knolls | 1 |
Christchurch | 1 |
Dublin | 1 |
Fleming Island | 1 |
Hangzhou | 1 |
Jersey City | 1 |
London | 1 |
Milan | 1 |
New Orleans | 1 |
New York | 1 |
Pioltello | 1 |
Sant'Ilario d'Enza | 1 |
Saronno | 1 |
Shenzhen | 1 |
Tokyo | 1 |
Torrance | 1 |
Warsaw | 1 |
Yokohama | 1 |
Yongin-si | 1 |
Totale | 40 |
Nome | # |
---|---|
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study, file 70076709-9230-4229-b8b4-f748b95837e5 | 40 |
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01, file aa33ab4c-c98c-4e31-bcea-acf2537fcede | 9 |
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV, file 9fedc8b8-b53a-433f-9490-616917c9a41d | 1 |
Totale | 50 |
Categoria | # |
---|---|
all - tutte | 194 |
article - articoli | 0 |
book - libri | 0 |
conference - conferenze | 0 |
curatela - curatele | 0 |
other - altro | 0 |
patent - brevetti | 0 |
selected - selezionate | 0 |
volume - volumi | 0 |
Totale | 194 |
Totale | Lug | Ago | Sett | Ott | Nov | Dic | Gen | Feb | Mar | Apr | Mag | Giu | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022/2023 | 34 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 2 | 7 | 9 | 6 | 5 |
2023/2024 | 16 | 7 | 6 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Totale | 50 |